Mr. David Oxley has been appointed as Chief Business Officer of BIORCHESTRA. Mr. Oxley leads corporate strategy, including global commercial partnerships and capital markets outside Korea. Mr. Oxley has extensive experience developing corporate strategy, managing asset license arrangements, and global capital markets. With a unique combination of experience in next-generation genetic and cellular medicine, Mr. Oxley’s credentials include designing and prosecuting complex business plans for Hong Kong Listing in China and the Asia Pacific, commercializing first-in-category products, and leading complex cross-border licensing transactions. In addition, Mr. Oxley brings experience building high-performing global sales and marketing organizations to support the company’s strategic plan. Beyond his corporate experience, Mr. Oxley has served on the boards of a privately held antibody-based medical device company, a not-for-profit foundation focused on infectious diseases in Africa, and as a member of the private sector delegation to the Global Fund to fight infectious diseases in Africa. Mr. Oxley completed his bachelor’s studies at Portland State University and his master’s in government and public health at Johns Hopkins University in the U.S.
12:00 PM - 12:15 PM
Thursday, June 8